Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Size Of Drug Discounts In Part D Employer-Sponsored Plans At Stake In Debate Over CMS Proposal

Executive Summary

The biopharmaceutical industry is fighting a CMS proposal that would impact the size of manufacturer discounts on drugs provided in the Medicare Part D coverage gap in an emerging type of Part D coverage for retirees – employer-sponsored group waiver plans, known as EGWPs.

You may also be interested in...



PhRMA Urges Caution In Implementing Part D “Trial-Size” Prescriptions

The Pharmaceutical Research and Manufacturers of America, as well as pharmacy and PBM groups, recommend that CMS test its proposed policy to institute trial-size prescriptions before implementing it on a widespread basis to Medicare Part D.

Nursing Home Overprescribing: Pharmacist Independence Requirement Should Start As Demo, APhA Says

CMS’ proposal to reduce overprescribing in nursing homes draws cautiously favorable response from national pharmacist group, but long-term care pharmacy firm Omnicare argues the agency has not provided adequate justification for its plan.

Medicare Part D Protected Classes Targeted in Last-Minute Payment Demo Update

If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel